Featured Content

Latest News

VIEW ALL
Addressing the Federal Cannabis Scheduling Quandary
Recent discussions within the US Department of Health and Human Services (HHS) and President Biden’s administration about relocating cannabis to Schedule III of the federal Controlled Substances Act have sparked optimism, with projections suggesting action before the 2024 presidential election.1 This article explores the historical complexities surrounding the legality of cannabis use, emphasizing the current…
Pharmaceutical and Natural Product Divide: Fostering Collaboration
By not working together, the pharmaceutical and cannabis/natural products industries are missing a major opportunity to advance human health care.
A Comprehensive Framework for Assessing Therapeutic Quality in Medical Cannabis
Not all cannabis products are equal in achieving optimal therapeutic results.
Cannabis for Tourette Syndrome: Psychiatrist Kirsten Müller-Vahl, MD, Shares her Clinical and Research Experience 
A German psychiatrist whose fascination with Tourette syndrome led her to become a cannabis expert is now President of the International Alliance for Cannabinoid Medicines (IACM).
CBD and CBG Show Analgesic Properties in Post-Fracture Pain
A preclinical study has shown that cannabidiol (CBD) and cannabigerol (CBG) were able to normalize pain sensitivity to hot, cold, and mechanical stimuli in mice with fractured tibiae. The study, published in Bone and Mineral Research, found the analgesic effects were similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs). “Here, we use a mouse model…

Current Issue

VIEW ARCHIVE October 2023  |   VOLUME 4, ISSUE 2